{
    "nctId": "NCT03593122",
    "briefTitle": "Investigation on the Efficacy of WO 2085 Moisturising Cream for Breast Cancer Patients Suffering From Vulvovaginal Dryness",
    "officialTitle": "Multicentric Study on the Application of WO 2085 Moisturising Cream for Breast Cancer Patients Suffering From the Symptoms of Vulvovaginal Dryness",
    "overallStatus": "COMPLETED",
    "conditions": "Vulvovaginal Atrophy",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 128,
    "primaryOutcomeMeasure": "Change from Baseline of subjective vulvovaginal atrophy symptoms (e.g. feeling of dryness, itching)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women with breast cancer undergoing chemotherapy OR therapy with aromatase inhibitors or anti-oestrogens (either at present or up to 3 months after ending treatment) AND with symptoms of vulvovaginal dryness since the start of tumour treatment\n* Written declaration of consent for the voluntary participation in the study is present\n\nExclusion Criteria:\n\n* Women who suffered symptoms of vulvovaginal dryness prior to the start of tumour treatment\n* Patients undergoing radiation therapy\n* Patients with other tumours\n* A current vaginal infection\n* Medical conditions related to the vulva or vagina\n* Current additional therapy of vulvovaginal dryness or vulvovaginal atrophy\n* Women who are not able to participate properly in this study\n* Current alcohol and/or drug abuse\n* Pregnant or lactating women",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}